Compare $CNSY vs $KPTI | Chartloom

Compare

$CNSY vs $KPTI

Plus Therapeutics Inc · Karyopharm Therapeutics Inc

CNSY

Plus Therapeutics Inc

KPTI

Karyopharm Therapeutics Inc

Compare $CNSY vs $KPTI

Comparing Plus Therapeutics Inc and Karyopharm Therapeutics Inc

CNSYPlus Therapeutics Inc

KPTIKaryopharm Therapeutics Inc

CNSYPlus Therapeutics Inc

Market cap

$13M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

1.12x

Rev growth (TTM)

—

YTD performance

-45.2%

52W performance

-45.2%

FCF yield

-267.6%

KPTIKaryopharm Therapeutics Inc

Market cap

$14M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.10x

Rev growth (TTM)

6.8%

YTD performance

-91.6%

52W performance

-89.7%

FCF yield

-476.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CNSY

KPTI

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

CNSY$13M

KPTI$14M

Enterprise Value

CNSY$11M

KPTI$281M

Price

CNSY$1.93

KPTI$0.61

P/E Ratio

CNSYN/A

KPTIN/A

P/S Ratio

CNSY3.16x

KPTI0.09x

EV/Sales

CNSY2.60x

KPTI1.92x

EV/EBITDA

CNSY0.00x

KPTI0.00x

P/B Ratio

CNSY2.22x

KPTI0.36x

P/FCF Ratio

CNSYN/A

KPTIN/A

EV/FCF

CNSY-0.31x

KPTI-4.30x

PEG Ratio

CNSYN/A

KPTIN/A

Forward P/E (NTM)

CNSYN/A

KPTIN/A

Forward P/S (NTM)

CNSY1.12x

KPTI0.10x

Revenue (TTM)

CNSY$4M

KPTI$147M

Revenue Growth (YoY)

CNSYN/A

KPTI6.8%

Forward Rev Growth

CNSY216.6%

KPTI27.7%

Gross Margin (TTM)

CNSY0.0%

KPTI95.9%

Operating Margin (TTM)

CNSY0.0%

KPTI0.0%

EBITDA Margin (TTM)

CNSY-612.0%

KPTI-56.1%

Net Margin (TTM)

CNSY-620.7%

KPTI-153.3%

FCF Margin (TTM)

CNSY-845.3%

KPTI-44.6%

Net Income (TTM)

CNSY$-26M

KPTI$-225M

FCF (TTM)

CNSY$-36M

KPTI$-65M

EPS (TTM)

CNSY-$3.78

KPTI-$7.77

ROE (TTM)

CNSY-39417.0%

KPTI-18243.0%

ROA (TTM)

CNSY-15136.0%

KPTI-20094.0%

ROIC (TTM)

CNSY-37414.0%

KPTI-6632.0%

Cash

CNSY$2M

KPTI$55M

Debt

CNSY$0

KPTI$322M

Net Cash/Debt

CNSY$2M

KPTI$-267M

Current Ratio (TTM)

CNSY1.37x

KPTI0.79x

Quick Ratio (TTM)

CNSY1.26x

KPTI0.71x

Debt/Equity (TTM)

CNSY0.19x

KPTI3.78x

Debt/Assets (TTM)

CNSY0.0%

KPTI0.0%

Interest Coverage (TTM)

CNSYN/A

KPTIN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

KPTI0.00x

Beta

CNSY2.21

KPTI1.14

52W Performance

CNSY-45.2%

KPTI-89.7%

YTD Performance

CNSY-45.2%

KPTI-91.6%

% from 52W High

CNSY-53.6%

KPTI-94.5%

% from 52W Low

CNSY30.0%

KPTI7.1%

Asset Turnover (TTM)

CNSY0.24x

KPTI1.31x

FCF Yield (TTM)

CNSY-267.6%

KPTI-476.7%

Earnings Yield (TTM)

CNSY-196.5%

KPTI-1639.3%

Dividend Yield (TTM)

CNSYN/A

KPTIN/A

Rule of 40

CNSY-845.3

KPTI-37.8

EV/GP/RG

CNSYN/A

KPTI0.07

Ticker research

View CNSY research View KPTI research

Metric	CNSY Plus Therapeutics Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$11M	$281M
Price	$1.93	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	0.09x
EV/Sales	2.60x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	0.10x
Revenue & Growth
Revenue (TTM)	$4M	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	216.6%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	-56.1%
Net Margin (TTM)	-620.7%	-153.3%
FCF Margin (TTM)	-845.3%	-44.6%
Net Income (TTM)	$-26M	$-225M
FCF (TTM)	$-36M	$-65M
EPS (TTM)	-$3.78	-$7.77
ROE (TTM)	-39417.0%	-18243.0%
ROA (TTM)	-15136.0%	-20094.0%
ROIC (TTM)	-37414.0%	-6632.0%
Financial Health
Cash	$2M	$55M
Debt	$0	$322M
Net Cash/Debt	$2M	$-267M
Current Ratio (TTM)	1.37x	0.79x
Quick Ratio (TTM)	1.26x	0.71x
Debt/Equity (TTM)	0.19x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	1.14
52W Performance	-45.2%	-89.7%
YTD Performance	-45.2%	-91.6%
% from 52W High	-53.6%	-94.5%
% from 52W Low	30.0%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	1.31x
FCF Yield (TTM)	-267.6%	-476.7%
Earnings Yield (TTM)	-196.5%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View CNSY research	View KPTI research

Valuation

P/S Ratio

KPTI

0.09x

CNSY

3.16x

EV/FCF

KPTI

-4.30x

CNSY

-0.31x

Growth & revenue

Revenue Growth TTM

KPTI

6.8%

Forward Revenue Growth

CNSY

216.6%

KPTI

27.7%

Profitability & performance

Gross Margin

KPTI

95.9%

CNSY

0.0%

ROE

KPTI

-18243.0%

CNSY

-39417.0%

FCF Yield %

CNSY

-267.6%

KPTI

-476.7%

52-Week Performance

CNSY

-45.2%

KPTI

-89.7%

Detailed metrics comparison

CNSY

Plus Therapeutics Inc

KPTI

Karyopharm Therapeutics Inc

Market Cap

CNSY$13M

KPTI$14M

Enterprise Value

CNSY$11M

KPTI$281M

Price

CNSY$1.93

KPTI$0.61

P/E Ratio

CNSYN/A

KPTIN/A

P/S Ratio

CNSY3.16x

KPTI0.09x

EV/Sales

CNSY2.60x

KPTI1.92x

EV/EBITDA

CNSY0.00x

KPTI0.00x

P/B Ratio

CNSY2.22x

KPTI0.36x

P/FCF Ratio

CNSYN/A

KPTIN/A

EV/FCF

CNSY-0.31x

KPTI-4.30x

PEG Ratio

CNSYN/A

KPTIN/A

Forward P/E (NTM)

CNSYN/A

KPTIN/A

Forward P/S (NTM)

CNSY1.12x

KPTI0.10x

Revenue (TTM)

CNSY$4M

KPTI$147M

Revenue Growth (YoY)

CNSYN/A

KPTI6.8%

Forward Rev Growth

CNSY216.6%

KPTI27.7%

Gross Margin (TTM)

CNSY0.0%

KPTI95.9%

Operating Margin (TTM)

CNSY0.0%

KPTI0.0%

EBITDA Margin (TTM)

CNSY-612.0%

KPTI-56.1%

Net Margin (TTM)

CNSY-620.7%

KPTI-153.3%

FCF Margin (TTM)

CNSY-845.3%

KPTI-44.6%

Net Income (TTM)

CNSY$-26M

KPTI$-225M

FCF (TTM)

CNSY$-36M

KPTI$-65M

EPS (TTM)

CNSY-$3.78

KPTI-$7.77

ROE (TTM)

CNSY-39417.0%

KPTI-18243.0%

ROA (TTM)

CNSY-15136.0%

KPTI-20094.0%

ROIC (TTM)

CNSY-37414.0%

KPTI-6632.0%

Cash

CNSY$2M

KPTI$55M

Debt

CNSY$0

KPTI$322M

Net Cash/Debt

CNSY$2M

KPTI$-267M

Current Ratio (TTM)

CNSY1.37x

KPTI0.79x

Quick Ratio (TTM)

CNSY1.26x

KPTI0.71x

Debt/Equity (TTM)

CNSY0.19x

KPTI3.78x

Debt/Assets (TTM)

CNSY0.0%

KPTI0.0%

Interest Coverage (TTM)

CNSYN/A

KPTIN/A

Net Debt/EBITDA (TTM)

CNSY0.00x

KPTI0.00x

Beta

CNSY2.21

KPTI1.14

52W Performance

CNSY-45.2%

KPTI-89.7%

YTD Performance

CNSY-45.2%

KPTI-91.6%

% from 52W High

CNSY-53.6%

KPTI-94.5%

% from 52W Low

CNSY30.0%

KPTI7.1%

Asset Turnover (TTM)

CNSY0.24x

KPTI1.31x

FCF Yield (TTM)

CNSY-267.6%

KPTI-476.7%

Earnings Yield (TTM)

CNSY-196.5%

KPTI-1639.3%

Dividend Yield (TTM)

CNSYN/A

KPTIN/A

Rule of 40

CNSY-845.3

KPTI-37.8

EV/GP/RG

CNSYN/A

KPTI0.07

Ticker research

View CNSY research View KPTI research

Metric	CNSY Plus Therapeutics Inc	KPTI Karyopharm Therapeutics Inc
Market & Valuation
Market Cap	$13M	$14M
Enterprise Value	$11M	$281M
Price	$1.93	$0.61
P/E Ratio	N/A	N/A
P/S Ratio	3.16x	0.09x
EV/Sales	2.60x	1.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.22x	0.36x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.31x	-4.30x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	1.12x	0.10x
Revenue & Growth
Revenue (TTM)	$4M	$147M
Revenue Growth (YoY)	N/A	6.8%
Forward Rev Growth	216.6%	27.7%
Profitability
Gross Margin (TTM)	0.0%	95.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-612.0%	-56.1%
Net Margin (TTM)	-620.7%	-153.3%
FCF Margin (TTM)	-845.3%	-44.6%
Net Income (TTM)	$-26M	$-225M
FCF (TTM)	$-36M	$-65M
EPS (TTM)	-$3.78	-$7.77
ROE (TTM)	-39417.0%	-18243.0%
ROA (TTM)	-15136.0%	-20094.0%
ROIC (TTM)	-37414.0%	-6632.0%
Financial Health
Cash	$2M	$55M
Debt	$0	$322M
Net Cash/Debt	$2M	$-267M
Current Ratio (TTM)	1.37x	0.79x
Quick Ratio (TTM)	1.26x	0.71x
Debt/Equity (TTM)	0.19x	3.78x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.21	1.14
52W Performance	-45.2%	-89.7%
YTD Performance	-45.2%	-91.6%
% from 52W High	-53.6%	-94.5%
% from 52W Low	30.0%	7.1%
Efficiency & Yields
Asset Turnover (TTM)	0.24x	1.31x
FCF Yield (TTM)	-267.6%	-476.7%
Earnings Yield (TTM)	-196.5%	-1639.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-845.3	-37.8
EV/GP/RG	N/A	0.07
Ticker research	View CNSY research	View KPTI research